Cancer BiologyCell Death and DiseasePeer-reviewed
Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemia
Rósula García‐Navas, Carmela Gómez, Anabel Clemente-Serrano…·Eugenio Santos
This study shows that combining SOS1 inhibitor BI-3406 with BCR/ABL TKIs like imatinib improves survival and overcomes resistance in CML models.